Navigation Links
Patient Safety Technologies Appoints New Chief Financial Officer
Date:10/27/2010

TEMECULA, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Patient Safety Technologies, Inc. (the "Company") (OTCBB: PSTX) today announced the appointment of David Dreyer as Vice President and Chief Financial Officer.  Mr. Dreyer will be responsible for the finance, accounting and reporting requirements for the Company and its wholly-owned operating subsidiary, SurgiCount Medical, as well as play a key role in various strategic initiatives and operational improvements.

"We are pleased to welcome David to the team and look forward to the addition of a proven healthcare executive with a depth of public company experience," said Brian E. Stewart, President and Chief Executive Officer.  

Mr. Dreyer is a certified public accountant and brings over 20 years of experience as a Chief Financial Officer and senior executive in the healthcare industry.  He has been the CFO of multiple publicly traded companies and has worked for a wide range of organizations in his career, including AMN Healthcare Services, AlphaStaff Inc., Sicor, Inc., Elan Pharma, Athena Neurosciences, Syntex Corporation and Arthur Andersen & Company.  David brings an extensive background in SEC reporting, corporate governance and SOX compliance as well as financial reporting, forecasting and the implementation of ERP systems.  He has successfully led numerous financings as well as a variety of strategic M&A and divestiture transactions.

"I am very excited at the future opportunities SurgiCount Medical offers, and look forward to working with Brian, the board of directors and the entire management team," commented Mr. Dreyer.

About Patient Safety Technologies, Inc. and SurgiCount Medical

Patient Safety Technologies, Inc., through its wholly owned operating subsidiary SurgiCount Medical, Inc., provides the Safety-Sponge® System, a solution proven to improve patient safety and reduce healthcare costs by preventing one of the most common errors in surgery, retained foreign objects.  For more information, contact SurgiCount Medical, Inc. at (951) 587-6201 or visit www.surgicountmedical.com.

Some statements in this release may be "forward-looking statements" for the purposes of the Private Securities Litigation Reform Act of 1995.  In some cases forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.  These factors, risks and uncertainties are discussed in Patient Safety Technologies, Inc. Annual Report on Form 10-K for the year ended December 31, 2009, as updated from time to time in our filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Patient Safety Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
(Date:5/3/2016)... COLOGNE, Germany , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to ... http://photos.prnewswire.com/prnh/20160503/362920    Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... Ariz. , May 3, 2016  As a ... twice contracted rheumatic fever, which damaged his heart. He ... But by June 2013, Shepherd,s heart was giving ... from death. On June 20, 2013, the ... Total Artificial Heart (TAH-t). Like a heart transplant, the ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Registration is now open for the 31st annual ... at the Hatch Memorial Shell on the Esplanade. The event regularly draws thousands of participants, ... is a competitive, timed event fully sanctioned by the USA Track & Field Association. ...
(Date:5/3/2016)... ... ... Elizabeth Murray has always loved walking one to two miles a day. ... and one on her arm. But she got to the point where she could ... , The valves of the heart wouldn’t close properly resulting in mitral regurgitation, where ...
(Date:5/3/2016)... ... 03, 2016 , ... Empyrean Benefit Solutions, Inc., the Hi-Touch ... center in La Vergne, Tennessee, near Nashville. The new center will complement Empyrean’s ... client services. , “Our Nashville-area center allows us to achieve several goals,” said ...
(Date:5/3/2016)... , ... May 03, 2016 , ... Ogawa World USA ... its user friendly Samsung tablet and exclusive Smart Application. The Smart 3D combines the ... each massage with a customized user profile and specialized massage program, each user has ...
(Date:5/3/2016)... ... May 03, 2016 , ... Dr. Poneh Ghasri, cosmetic dentist in West ... new and existing patients. Cosmetic dentistry allows patients to improve the aesthetics of their ... with some minor or more serious cosmetic flaws. These specials allow patients to achieve ...
Breaking Medicine News(10 mins):